Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic utility of novel marker TRIM63 ISH in the workup of uterine perivascular epithelioid cell tumors.

Virchows Archiv : an international journal of pathology·2026
Same author

Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li-Fraumeni syndrome.

Histopathology·2026
Same author

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026
Same author

Prevalence of allergic diseases and evaluation of total IgE and blood eosinophils as diagnostic biomarkers in Colombia, a tropical country.

The World Allergy Organization journal·2026
Same author

Knowledge among primary care physicians on urticaria treatment: Impact of educational interventions.

The journal of allergy and clinical immunology. Global·2026
Same author

Clonal lineage tracing of innate immune cells in human cancer.

Cancer cell·2026

Related Experiment Video

Updated: Apr 23, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Targeted genomic analysis of Müllerian adenosarcoma.

Brooke E Howitt1, Lynette M Sholl, P Dal Cin

  • 1Women's and Perinatal Pathology Division, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.

The Journal of Pathology
|September 19, 2014
PubMed
Summary

Genomic analysis of Müllerian adenosarcoma (MA) reveals copy number variations, not mutations, distinguish tumors with sarcomatous overgrowth (SO). These findings may lead to new diagnostic and prognostic tools for this rare cancer.

Keywords:
HMGA2MDM2MYBL1Müllerianadenosarcomasarcomagenesis

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.2K

Related Experiment Videos

Last Updated: Apr 23, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.2K

Area of Science:

  • Gynecologic Oncology
  • Cancer Genomics
  • Pathology

Background:

  • Müllerian adenosarcoma (MA) is a rare female genital tract tumor with malignant stroma and benign epithelium.
  • Sarcomatous overgrowth (SO) is the sole histological predictor of poorer prognosis in MA.
  • Current diagnostic and prognostic tools for MA lack specific molecular or immunohistochemistry (IHC) markers.

Purpose of the Study:

  • To investigate genomic mutations and copy number variations (CNVs) in MA.
  • To elucidate the pathobiology of MA and identify potential diagnostic and prognostic biomarkers.
  • To correlate genomic findings with histological subtypes, specifically the presence or absence of SO.

Main Methods:

  • DNA extraction from 20 MA samples (18 subjects), including areas with and without SO.
  • Targeted next-generation sequencing (NGS) of 275 cancer genes for mutations and CNVs.
  • Analysis of 91 introns across 30 genes for cancer-associated rearrangements.
  • Immunohistochemistry (IHC) for CDK4, MDM2, and HMGA2 expression.

Main Results:

  • No significant difference in the mean number of mutations between MA with and without SO.
  • MA with SO showed significantly higher mean numbers of gene-level CNVs compared to MA without SO (24.6 vs. 5; p=0.0002).
  • Frequent amplifications of MDM2 and CDK4 (28%) and MYBL1 (22%) were observed, with MYBL1 amplification predominantly in SO.
  • Alterations in the PIK3CA/AKT/PTEN pathway were present in 72% of cases.
  • TP53 mutations were rare (2 cases, both with SO); ATRX mutations were associated with SO (3 cases, 17%).
  • No chromosomal rearrangements were detected.

Conclusions:

  • Recurrent genomic alterations, particularly CNVs, are identified in MA.
  • Specific CNVs, such as MDM2, CDK4, and MYBL1 amplifications, are associated with MA, and some correlate with sarcomatous overgrowth.
  • These genomic findings represent potential novel diagnostic and prognostic markers for MA, warranting further investigation.